NIO-752
- Generic Name
- NIO-752
A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK
Phase 1
Not yet recruiting
- Conditions
- Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder)Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder)Alzheimer Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- University College, London
- Target Recruit Count
- 10
- Registration Number
- NCT06372821
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
Phase 1
Recruiting
- Conditions
- Mild Cognitive ImpairmentAlzheimer Disease
- Interventions
- Drug: Matching placebo
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT05469360
- Locations
- 🇸🇪
Novartis Investigative Site, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath